PDCD1 and non-small cell lung carcinoma: As discussed by Roy Herbst from Yale University, the combination of chemotherapy with PD-1 inhibitor pembrolizumab as a first-line therapy for metastatic non-small cell lung cancer (NSCLC) was effective.